Linkedin X-twitter Youtube
Launch Digital Edition

Webinars and Sponsored Roundtables — Register Now

Tuesday, April 28, 2026, 12:00 PM–1:00 PM ET
Discover how next-day comprehensive genomic profiling (CGP) is possible with the Oncomine Comprehensive Assay Plus on the Genexus System—delivering both speed and accuracy.

Webinar presenters Jane Bayani, MHSc, PhD, Assistant Professor and Co-Director, Diagnostic Development, Ontario Institute for Cancer Research, Canada, and Nicola Normanno, MD, Scientific Director, IRCCS Romagnolo Institute for the Study of Tumors, Italy, and Morten Grauslund, PhD, Molecular Biologist, Department of Pathology, Rigshospitalet/Copenhagen University Hospital, Copenhagen, Denmark.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Thermo Fisher Scientific. For Research Use Only. Not for use in diagnostic applications. 

Register Now

Thursday, April 30, 2026, 11:00 AM–12:00 PM ET
Hear an expert discuss how Memorial Sloan Kettering Cancer Center (MSKCC) is utilizing
the oncoReveal® Nexus 21-gene panel to redefine turnaround time and actionable insights
in cancer care. Dr. Ewalt shares a perceptive look at the clinical need for rapid, front-line NGS sequencing, and how a unique, purpose built targeted NGS panel (Pillar Biosciences’ oncoReveal Nexus 21 gene Panel) was developed, validated and implemented clinically by Memorial Sloan Kettering Cancer Center (MSK-REACT) to complement their current comprehensive genomic profiling (CGP) approach.

Webinar presenter Mark Ewalt, MD, Associate Medical Director for Laboratory Operations for Diagnostic Molecular Pathology in the Molecular Diagnostics Service, Department of Pathology and Laboratory Medicine, MSKCC.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Pillar Biosciences.

Register Now

Thursday, May 28, 2026, 1:00–2:00 PM ET
This session is designed to improve understanding and application of recent updates to synoptic pathology reporting protocols such as the latest Reporting Template for Reporting Results of Biomarker Testing of Specimens from Patients with Carcinoma of the Breast. These changes reflect evolving clinical guidelines that directly influence diagnostic accuracy and treatment selection in breast cancer care.

Webinar presenters Thaer Khoury, MD, FCAP, Chair, Pathology and Laboratory Medicine, Roswell Park Comprehensive Cancer Cente, and Colin Murphy,  CEO of mTuitive.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Subspecialties

Interactive Product Guides

All Issues

Pathology informatics selected abstracts

October 2024—The authors conducted a study to evaluate the Genius digital diagnostic system compared with manual light microscopy diagnosis using ThinPrep Pap test slides. Six cytologists and three cytopathologists participated in the study. They received 1.5 days of training on the Genius digital system from the manufacturer (Hologic, Marlborough, Mass.). They then analyzed 319 ThinPrep Pap test cases in the authors’ institutional cytology archive that represented a range of Bethesda System categories typically encountered in routine practice. The study participants assessed diagnostic accuracy by comparing digital and manual results to the original Pap test diagnosis, which was considered the reference diagnosis, or ground truth.

Newsbytes

October 2024—Conducting informal pathology clinics in his office to help patients better understand their diagnosis has been standard fare for John Groth, MD. But this will change in the coming months as he finishes setting up a formal clinic, replete with the technology and tools necessary to more easily educate patients at Endeavor Health’s Evanston Hospital.

Q&A column

October 2024
Q. Immunofluorescence microscopy results for antinuclear antibodies (ANAs) are reported as a titer. How can we best comply with CAP checklist requirement IMM.34120 Daily QC—Nonwaived Tests for ANA testing? Read answer.
Q. Is there a standard of care for anatomic pathology reporting? The CAP document “How to Read Your Pathology Report” states that pathologists “always perform the microscopic evaluation of a specimen, even if the final pathology report does not include a written description.” Must the testing pathology laboratory provide the patient with the microscopic description if it is requested and not included in the pathology report? Read answer.

Put It on the Board

October 2024—The two lawsuits filed by the American Clinical Laboratory Association and Association for Molecular Pathology that challenge the Food and Drug Administration’s final rule on laboratory-developed tests will be consolidated in the U.S. District Court for the Eastern District of Texas, according to a motion filed Sept. 9. During the weeks of Aug. 26 and Sept. 2, the parties to both actions conferred on how to litigate both cases “in a just, speedy, and efficient manner,” the motion says. It adds that all parties in both cases consent to the transfer of the AMP case to the Eastern District “and agree that, subject to this Court’s discretion, the two cases then should be consolidated for joint briefing and decision.”

In memoriam

October 2024—Frederick L. “Fritz” Kiechle, MD, PhD, editor of the CAP TODAY “Q&A” column from 2008 to 2024, died on July 30 at age 78. “He was a champion for clinical pathology, a champion for the laboratory. He was an innovator in clinical chemistry,” and “devoted to resident education,” says Dorothy Adcock, MD, chair of the CAP Publications Committee and former chief medical officer, Labcorp. Dr. Kiechle was an author of the CAP Publications manual So You’re Going to Collect a Blood Specimen, through its soon-to-be 16th edition. He wrote Disruptive Technologies in Clinical Medicine, which the CAP published in 2023. He was a member of the CAP Publications Committee from 1993 to this year, having served 12 of those years as an advisor. He was a member of the Archives of Pathology & Laboratory Medicine editorial board (2006–2023), member and then chair of the Patient Preparation and Specimen Handling editorial board (1993–1996), and a member of the Chemistry (2008–2013) and Special Chemistry (2006–2007) resource committees.

New Enhertu use, new HER2 complexities

September 2024—Every profession has its own news cycle. In pathology, the story arc is often a lengthy one, stretching from clinical triumph to Now what? Such is the case with expanded use of trastuzumab deruxtecan, which was granted accelerated FDA approval in late April for adult patients with unresectable or metastatic HER2-positive (IHC 3+) solid tumors who received prior systemic treatment and have no alternative treatment options. Three multicenter trials evaluated the efficacy of the drug: DESTINY-PanTumor02, DESTINY-Lung01, and DESTINY-CRC02. PanTumor02 looked at seven tumor cohorts: endometrial, cervical, ovarian, bladder, biliary tract, pancreatic, and other solid cancers (excluding breast, colorectal, gastric, and non-small cell lung cancers). The results of these trials often were striking (median duration of response for PanTumor02 was 19.4 months, for example), and physicians are now looking closely at this tumor-agnostic (also referred to as tissue-agnostic) indication.

Intraop neuropathology consultation: tips and cases

September 2024—Leomar Ballester, MD, PhD, of the University of Texas MD Anderson Cancer Center has simple advice for those called to provide an intraoperative neuropathologic consultation: review the imaging and know the entities.

Self-collected vaginal swabs studied for HPV tests

September 2024—In HPV primary screening, self-collected vaginal samples enable accurate clinical HPV testing, and neither extended ambient dry storage nor exposure to extreme temperatures influence HPV detection, say the authors of a study published in June.

Host response solutions to sepsis risk prediction

September 2024—When emergency physician Chadd Kraus, DO, DrPH, of Lehigh Valley Health Network in Allentown, Pa., sees a patient who could have sepsis, he wants to know if there’s an infection and, if so, how bad it is based on the patient’s host response, what interventions are needed, and whether the patient will need to be hospitalized.

Eyes on LDT inventory and cyberattack readiness

September 2024—The ADLM meeting in Chicago had just wrapped up when Compass Group members met online Aug. 6 with CAP TODAY publisher Bob McGonnagle. Stan Schofield, Compass Group VP and managing principal, noted Allina Health had announced in late June its definitive agreement with Quest Diagnostics for select assets of Allina’s laboratory services business, and Schofield reported plenty of M&A talk at the ADLM meeting. The group’s August discussion began there and moved to laboratory-developed tests and cybersecurity.

MARKETPLACE

TRENDING